Complete Filing Data
IceCure Medical Ltd. reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents of $8.90 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean IceCure Medical Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$15.1M | -$15.3M | -$14.7M | -$17.0M | -$9.9M | -$3.7M |
| Revenue * | $3.4M | $3.3M | $3.2M | $3.1M | $4.1M | $3.9M |
| Research And Development Expense | $7.4M | $7.1M | $8.3M | $9.1M | $5.9M | $3.8M |
| Operating Income Loss | -$15.1M | -$15.7M | -$15.6M | -$16.7M | -$9.7M | -$4.1M |
| Nonoperating Income Expense | $37.0K | $378.0K | $924.0K | -$239.0K | -$171.0K | $412.0K |
| Gross Profit | $1.2M | $1.5M | $1.3M | $1.4M | $2.2M | $2.4M |
| General And Administrative Expense | $4.5M | $3.8M | $4.2M | $5.9M | $4.1M | $1.7M |
| Cost Of Revenue | $2.2M | $1.8M | $1.9M | $1.6M | $1.9M | $1.4M |
| Selling And Marketing Expense | $4.4M | $6.3M | $4.4M | $3.2M | $1.9M | |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$17.0M | -$9.9M | -$3.7M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $8.9M | $7.6M | $10.5M | $23.7M | $25.6M | $3.5M | $5.8M |
| Stockholders Equity | $9.1M | $6.9M | $12.2M | $25.4M | $27.0M | $5.6M | $3.3M |
| Retained Earnings Accumulated Deficit | -$120.4M | -$105.4M | -$90.1M | -$75.4M | -$58.4M | -$48.5M | |
| Property Plant And Equipment Net | $993.0K | $1.3M | $1.5M | $1.4M | $713.0K | $307.0K | |
| Operating Lease Liability Current | $204.0K | $298.0K | $223.0K | $167.0K | $224.0K | $214.0K | |
| Liabilities Noncurrent | $13.0K | $161.0K | $376.0K | $430.0K | $1.3M | $877.0K | |
| Liabilities Current | $4.8M | $5.5M | $3.9M | $4.3M | $4.0M | $3.7M | |
| Liabilities And Stockholders Equity | $13.9M | $12.6M | $16.4M | $30.2M | $32.3M | $10.2M | |
| Inventory Net | $2.6M | $2.0M | $2.3M | $2.9M | $2.0M | $1.1M | |
| Cash And Cash Equivalents At Carrying Value | $8.9M | $7.6M | $10.5M | $23.7M | $25.6M | $3.5M | |
| Assets Noncurrent | $1.3M | $1.8M | $2.2M | $2.1M | $2.0M | $650.0K | |
| Assets Current | $12.6M | $10.8M | $14.2M | $28.1M | $30.3M | $9.6M | |
| Assets | $13.9M | $12.6M | $16.4M | $30.2M | $32.3M | $10.2M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $1.2M | -$2.9M | -$13.2M | -$1.6M | $22.1M | ||
| Accounts Receivable Net Current | $221.0K | $103.0K | $78.0K | $456.0K | $94.0K | ||
| Other Liabilities Current | $1.1M | $1.2M | $3.1M | $3.5M | $2.9M | $2.9M | |
| Operating Lease Liability Noncurrent | $161.0K | $376.0K | $430.0K | $685.0K | $118.0K | ||
| Accounts Payable Current | $502.0K | $714.0K | $881.0K | $645.0K | |||
| Finance Lease Right Of Use Asset | $668.0K | $913.0K | $306.0K | ||||
| Other Long Term Debt Noncurrent | $618.0K | $759.0K | |||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $41.0K | $116.0K | $193.0K | ||||
| Prepaid Expense And Other Assets Current | $752.0K | $981.0K | $744.0K | $1.2M | |||
| Operating Lease Right Of Use Asset | $239.0K | $524.0K | $679.0K | $668.0K | |||
| Increase In Inventory | $902.0K | $891.0K | $386.0K | ||||
| Exchange Rate Changes In Cash And Cash Equivalents And Short Time Deposits | $359.0K | $5.0K | -$452.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$1.6M | $22.1M | -$2.5M | ||||
| Exchange Rate Changes In Cash And Cash Equivalents And Deposit | -$39.0K | $25.0K | -$359.0K | -$5.0K | |||
| Prepaid Expenses And Other Longterm Assets | $34.0K | $333.0K | $37.0K | ||||
| Prepaid Expense And Other Assets Noncurrent | $46.0K | $34.0K | $34.0K | ||||
| Increase In Right Of Use Assets | -$245.0K | $607.0K | $81.0K | ||||
| Employee Related Liabilities Current | $2.7M | $2.8M | $3.1M | ||||
| Accounts Payable Trade Current | $863.0K | $1.2M | $502.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $1.4M | $869.0K | $1.3M | $1.9M | $316.0K | $229.0K |
| Payments To Acquire Property Plant And Equipment | $36.0K | $71.0K | $480.0K | $891.0K | $533.0K | $223.0K |
| Net Cash Provided By Used In Operating Activities | -$14.6M | -$12.6M | -$12.6M | -$14.3M | -$12.6M | -$3.7M |
| Net Cash Provided By Used In Investing Activities | -$36.0K | $446.0K | -$684.0K | -$891.0K | $3.8M | -$4.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$229.0K | $237.0K | -$496.0K | -$1.1M | $2.0M | -$121.0K |
| Increase Decrease In Other Current Liabilities | -$129.0K | $74.0K | -$168.0K | $540.0K | $60.0K | -$135.0K |
| Increase Decrease In Accounts Payable Trade | -$369.0K | $730.0K | -$212.0K | -$167.0K | $236.0K | $217.0K |
| Increase Decrease In Accounts Receivable | $110.0K | $118.0K | $25.0K | -$378.0K | $362.0K | $77.0K |
| Net Cash Provided By Used In Financing Activities | $15.8M | $9.2M | $83.0K | $13.6M | $30.9M | $5.9M |
| Increase Decrease In Operating Lease Liability | -$284.0K | -$256.0K | -$191.0K | -$312.0K | $577.0K | $92.0K |
| Proceeds From Issuance Of Common Stock | $9.2M | $13.6M | $14.6M | $5.8M | ||
| Increase Decrease In Inventories | $637.0K | -$287.0K | -$582.0K | $902.0K | $891.0K | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$39.0K | $25.0K | -$356.0K | $43.0K | $215.0K | |
| Stock Issued During Period Value Share Based Compensation | $1.9M | $316.0K | $229.0K | |||
| Increase Decrease In Other Operating Assets | -$327.0K | -$271.0K | -$182.0K | -$245.0K | $607.0K | |
| Increase Decrease In Other Noncurrent Liabilities | -$618.0K | -$141.0K | $432.0K | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $109.0K | -$39.0K | $25.0K | $43.0K | $215.0K | |
| Proceeds From Debt Net Of Issuance Costs | $1.1M | $487.0K | $931.0K | |||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $869.0K | $1.3M | $1.9M | $316.0K | ||
| Proceeds From Stock Options Exercised | $83.0K | $1.0K | $337.0K | |||
| Payments To Acquire Restricted Certificates Of Deposit | $296.0K | $15.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 63.6M | 50.9M | 45.6M | 37.0M | 28.5M | 17.1M |
| Earnings Per Share Basic | $0.24 | $0.30 | $0.32 | $0.46 | $0.35 | $0.22 |
| Weighted Average Number Of Diluted Shares Outstanding | 63.6M | 50.9M | 45.6M | 37.0M | 28.5M | 17.1M |
| Earnings Per Share Diluted | $0.24 | $0.30 | $0.32 | $0.46 | $0.35 | $0.22 |
| Common Stock Shares Outstanding | 73.1M | 56.6M | 45.7M | 45.6M | 35.8M | 20.2M |
| Common Stock Shares Issued | 73.1M | 56.6M | 45.7M | 45.6M | 35.8M | 20.2M |
| Common Stock Shares Authorized | 2.50B | 2.50B | 2.50B | 2.50B | 2.50B | 2.50B |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Depreciation | $295.0K | $332.0K | $323.0K | $248.0K | $127.0K | $63.0K |
| Additional Paid In Capital | $112.3M | $102.2M | $100.8M | $85.4M | $54.2M | |
| Stock Issued During Period Value Stock Options Exercised | $83.0K | $1.0K | $337.0K | $11.0K | ||
| Stock Issued During Period Value New Issues | $9.2M | $50.0M | $14.5M | $12.4M | ||
| Investment Of Deposits | -$1.4M | -$500.0K | $4.6M | -$4.4M | ||
| Stock Issued During Period Value Other | $15.5M | $6.0K | $14.6M | $5.8M | ||
| Other Prepaid Expense Current | $1.2M | $2.3M | $260.0K | |||
| Exercise Of Options To Ordinary Shares | 1.0K | 337.0K | 11.0K |
Most recent annual filing with the SEC: March 17, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.